
Ichnos Glenmark Innovation (IGI), the biotechnology joint venture of Glenmark Pharmaceuticals and Ichnos Sciences, has submitted an investigational new drug (IND) application to the US FDA for ISB 2301, a candidate designed to target solid tumours. The company plans to initiate a Phase I clinical trial in 2027, subject to regulatory clearance.

ISB 2301 is a pentaspecific molecule designed to target three tumour-associated antigens while activating T cells and natural killer (NK) cells. It was developed using IGI's proprietary BEAT multispecific platform. In preclinical studies, the drug showed favourable pharmacokinetic and tolerability profiles in non-human primates. The company is also developing ISB 2001 for multiple myeloma, which has shown anti-tumour activity in an early-stage trial. Glenmark's shares closed at ₹2,613.80 on 17 November.
Business Standard leads with the scientific details of ISB 2301's pentaspecific design and Lida Pacaud's statement, framing the IND filing as a milestone for IGI's oncology pipeline. CNBC TV18's version is more market-sensitive, adding Glenmark's share price movement (closing at ₹2,613.80, down 0.6%) and a disclaimer about preclinical results being animal studies only. The two outlets are otherwise uniform, carrying the same corporate announcement from the regulator. Neither adopts a critical or ideological stance. The balanced reading is that IGI has taken a defined regulatory step toward a Phase I trial in 2027, with the drug's actual clinical profile yet to be tested.
Coverage: 2 sources, 2 neutral
Sources (2): business-standard.com (neutral report), cnbctv18.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.